Key result
Sub-zero storage below -18 °C is linked to superior oral polio vaccine potency and integrity.
Why the study?
The status of cold chain infrastructure and potency of oral polio vaccine vials in Kenya were evaluated to assess vaccine effectiveness in field conditions.
Cross-Sectional (n=23)
Yes
The study demonstrates that oral polio vaccine potency is directly proportional to the Vaccine Vial Monitor stage and is maintained better at temperatures below -18 °C in Kenyan health centres.
May warrant closer cold-chain oversight in vaccine programs; leaves open whether VVM reliably predicts potency outside this cross-sectional setting.
Background: In 1988 the World Health Organization (WHO) proposed mass immunization campaigns with the trivalent oral polio vaccine (TOPV) among children less than 5 years of age. The Vaccine Vial Monitor (VVM) is a small patch of heat-sensitive material placed on the vaccine vial to register cumulative heat exposure. A direct relationship exists between the rate at which the VVM changes colour and ambient temperature. This in turn affects the potency of the oral polio vaccine. [1] Objectives: To evaluate the status of the cold chain infrastructure in Kenya and to determine the total TOPV virus concentration of retrieved field samples. Methods & Materials: A stratified multi-stage sampling strategy was used leading to selection of 14 health centres this study. A total of 23 TOPV vial samples were collected, separated into individual serotypes generating 69 samples for the potency test. Potency of oral polio vaccine was tested using Karber's formula. This was then compared to the Vaccine Vial Monitor stage of the vials Results: Our study showed that the average potency of polio vaccine serotype1, serotype 2 and serotype 3 were as follows; Comparison between VVM1/VVM 2 and Serotype titres calculatedTabled 1Polio 1 standard (Mean titre)Polio 1 Test (Calculated Mean Titre)Polio 2 standard (Mean titre)Polio 2 test (Calculated mean Titre)Polio 3 Standard (Mean titre)Polio 3 test (Calculated mean Titre)VVM106106.05105104.98105.5105.731106106.03105105.08105.5105.352 Open table in a new tab *The mean titre was calculated using the Karber's formula[Log CCID50 = L-d(S-0.5)]]with an allowance of + 0.5 log units Conclusion: On average the vaccine vials used in the study were potent with satisfactory VVM and mean serotype titre. We found that some OPV vials had dissatisfactory VVM stage. Vaccine potency was seen to be directly proportional to VVM stage of vaccine vials. Vaccine vials kept at temperatures below -18 °C had a better VVM leading to a better potency status. Some OPV Samples which had lower titre of serotype 2 were contributed to by the temperature of the equipment they were stored at. References Samant Y, Lanjewar H, Block L, Parker D, Stein B, Tomar G. Relationship between vaccine vial monitors and cold chain infrastructure in a rural district of India. Rural and Remote Health 7: 617. (Online) 2007. Available: http://www.rrh.org.au.
No takes yet. Share an insight, caveat, or question.
Hassan et al. (2014) reported a cross-sectional. Cold chain storage temperature was evaluated on Total TOPV virus concentration (potency). Oral polio vaccine potency was directly proportional to the Vaccine Vial Monitor stage, with vials stored below -18 °C maintaining better VVM and potency status.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: